Clinical trials and studies have reported that PD-1/PD-L1 inhibitors can significantly improve the outcomes of advanced non-small cell lung cancer (NSCLC) patients in recent decades (1–6), and PD-1/PD-L1 inhibitors are recommended as the standard first-line therapy for advanced or metastatic NSCLC by the National Comprehensive Cancer Network (NCCN) guidelines (7). This evidence concerns the gene CD274 and non-small cell lung carcinoma.